-
-
-
-
-
-
-
Vir Biotechnology (VIR) PT Raised to $18 at Needham
-
-
-
-
-
-
-
Astellas and Vir Biotechnology Announce Global Strategic Collaboration to Advance PSMA-targeting PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 for the Treatment of Prostate Cancer
-
-
-
-
-
-
-
Vir Biotechnology Inc. (VIR) Misses Q2 EPS by 10c, provides guidance
-
-
-
-
-
-
-
Vir Biotechnology Inc. (VIR) Tops Q4 EPS by 11c
-
-
-
-
-
-
-
Vir Biotechnology (VIR) Announces Closing of Exclusive Worldwide License Agreement With Sanofi for Multiple Potential Best-in-Class Clinical-Stage T-Cell Engagers
-
-
-
-
-
-
-
Vir Biotechnology Acts on Expanded Strategy of Powering the Immune System Through Exclusive Worldwide License Agreement with Sanofi for Multiple Potential Best-in-Class Clinical-Stage T-cell Engagers
-
-
-
-
-
-
-
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
-
1,217,557 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

